Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Helix BioPharma has signed an agreement with KBI Biopharma to develop a process for preparing L-DOS47 in a lyophilized vial format suitable for clinical testing.
Subscribe to our email newsletter
L-DOS47 combines Helix’s proprietary DOS47 new drug candidate with a highly specific single domain antibody to form a potential new targeted drug product for the treatment of adenocarcinoma of the lung.
John Docherty, president of Helix, said: “This new arrangement advances the company closer to its objective of initiating clinical testing with L-DOS47. The lyophilized packaging format will provide for optimum stability of L-DOS47 while in storage so that individual vials may be reconstituted in liquid form immediately prior to patient administration.”